ArticleInternational ophthalmology2026
LncRNA ANRIL inhibits TGF-β1-induced proliferation, migration, and fibrosis of Tenon's capsule fibroblasts from glaucoma patients by reducing IL-22-RA1 stability and expression.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the involvement of long non-coding RNA (lncRNA) Antisense Noncoding RNA in the INK4 Locus (ANRIL) in subconjunctival fibrosis after glaucoma filtration surgery (GFS). STUDY
designExperimental.
methodsPrimary human Tenon's capsule fibroblasts (HTFs) were isolated from glaucoma patients during GFS and then treated with human recombinant protein transforming growth factor-β1 (TGF-β1) to mimic the glaucoma condition in vitro. HTFs were pre-transfected with ANRIL-specific pcDNA3.1 overexpression vector (ANRIL-OE) for 48 h and then treated with TGF-β1 (10 ng/mL) for 48 h, followed by the detection of cell viability, proliferation, and migration by CCK-8 assay, EdU staining, and wound healing assay. The expression of fibrosis markers alpha-smooth muscle actin (α-SMA), fibronectin, and collagen I was determined by RT-qPCR and western blotting. The interaction between ANRIL and interleukin-22 receptor alpha 1 (IL-22-RA1) was verified through RNA pull-down, RNA Immunoprecipitation (RIP), and ubiquitination assays.
resultsOur data revealed that TGF-β1 downregulated ANRIL expression in HTFs. ANRIL overexpression suppressed TGF-β1-induced enhancement in cell viability, proliferation, migration, and extracellular matrix (ECM) deposition in HTFs. Mechanically, ANRIL negatively regulated the stability and expression of IL-22-RA1 by increasing IL-22-RA1 ubiquitination. IL-22-RA1 overexpression antagonized the repressive effects of ANRIL on the proliferation, migration, and fibrosis of TGF-β1-stimulated HTFs.
conclusionCollectively, ANRIL curbs TGF-β1-induced HTF activation and fibrosis by downregulating IL-22-RA1, which provides the rationale for developing strategies based on the ANRIL/IL-22-RA1 axis to prevent scar formation following GFS.
Indexed as
Identifiers
42484723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.